课题基金 / 基金详情

PILOT STUDY OF DCA EFFECTS ON HUMAN TYROSINE METABOLISM

PILOT STUDY OF DCA EFFECTS ON HUMAN TYROSINE METABOLISM
DCA 对人体酪氨酸代谢影响的初步研究
批准号:
7950768
负责人:
Peter Wallace Stacpoole
金额:
$0.22万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-12-01 至 2009-07-31

项目摘要

项目成果

Peter Wallace Stacpoole的其他基金

相似基金

相关文献

中文摘要
翻译
这个子项目是众多研究子项目之一
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. We propose to conduct a proof-of-concept investigation in 3 healthy adults who would receive 13C-U-tyrosine by vein before and after 5 days of 12.5 mg/kg/bid DCA, the typical clinical dose and dose schedule. We will determine tyrosine kinetics by standard kinetic modeling techniques we have employed previously and by GC/MS and LC/MS methods we have developed to identify and quantify both tyrosine and DCA and their metabolites.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Personalized dosing of dichloroacetate for the treatment of rare and common diseases
  • 批准号:
    10471783
  • 项目类别:
  • 资助金额:
    $98.53万
  • 财政年份:
    2017
  • 负责人:
    Peter Wallace Stacpoole
  • 依托单位:
Personalized dosing of dichloroacetate for the treatment of rare and common diseases
  • 批准号:
    10216314
  • 项目类别:
  • 资助金额:
    $99.28万
  • 财政年份:
    2017
  • 负责人:
    Peter Wallace Stacpoole
  • 依托单位:
Personalized dosing of dichloroacetate for the treatment of rare and common diseases
  • 批准号:
    9517985
  • 项目类别:
  • 资助金额:
    $69.51万
  • 财政年份:
    2017
  • 负责人:
    Peter Wallace Stacpoole
  • 依托单位:
Personalized dosing of dichloroacetate for the treatment of rare and common diseases
  • 批准号:
    10010536
  • 项目类别:
  • 资助金额:
    $100.0万
  • 财政年份:
    2017
  • 负责人:
    Peter Wallace Stacpoole
  • 依托单位:
国内基金
海外基金
Molecular Interaction Reconstruction of Rheumatoid Arthritis Therapies Using Clinical Data